Medicine, Healing Supplies Purchases Announced
After receiving concerns about a lack of medicines and supplies at the Institute of Health for Wellbeing (INSABI) during 2022, UNOPS and INSABI clarified the purchases already made and the plans to acquire more during their 3rd Joint Informative Session.
“To supply the country with medicines and medical supplies from January to June 2022, the purchase of 549 million pieces has already been made,” said Juan Ferrer, General Director, INSABI. The purchase is made up by 548 different medicines and 336 types of medical supplies.
Purchases for the second half of 2022 will correspond to 273 types of medical supplies, representing 116 million individual pieces, and 361 different medicines, representing 271 million individual pieces. During the session, representatives of both institutions also explained the distribution process.
The concerns regarding the distribution process stem from a report by Animal Politico stating that INSABI had only delivered 9.5 percent of all the drugs requested by the states in the consolidated purchase for 2021, according to the institution's official reports. INSABI’s official platform reportedly supplied 1.75 million items to the states from the requested 18.40 million.
Giuseppe Mancinelli, Deputy Director for Latin America and Mexico’s representative, UNOPS, said that 97 percent of the medication keys and 95 percent of healing material have been delivered according to the UNOPS schedule. Mancinelli stated that 270 million pieces were delivered by Nov. 26 and the remaining 60 million pieces are scheduled to be delivered in Dec. 2021.
Ferrer also addressed delayed payment for the laboratories supplying the orders. “We need to become more efficient on paying the bill of the laboratories working with us, nationally and internationally, they have made an outstanding effort that we must honor by paying in time,” he said.
The panel recognized that its supply process faced challenges but claimed they will continue to maintain open communication channels. “We are in the middle of a large-impact transition that asks for a multi-party commitment, which we have received from the industry. This is a global commitment between UNOPS and INSABI and we are thankful to be fulfilling,” said Mancinelli.
To this session, representatives from the pharmaceutical industry were present, among these were CANIFARMA, AMIIF, AMID, ANAFAM, ANADIM, AMEGI, CANACINTRA and CCE, among others.